Patents by Inventor Tim Carlton

Tim Carlton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDES
    Publication number: 20230287098
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: April 18, 2023
    Publication date: September 14, 2023
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Keith RAY
  • Compositions
    Patent number: 11684677
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: June 27, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Mike West, Keith Ray
  • VHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases
    Patent number: 11667719
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: June 6, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Lurdes Duarte, Martyn Symmons, Keith Ray
  • COMPOSITIONS
    Publication number: 20230143091
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-7R binding polypeptide.
    Type: Application
    Filed: June 19, 2020
    Publication date: May 11, 2023
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Keith RAY
  • IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
    Patent number: 11623952
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: April 11, 2023
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Marion Cubitt, Tim Carlton, Luana Maggiore, Lurdes Duarte, Kevin Roberts, Mike West
  • POLYPEPTIDES
    Publication number: 20230056445
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Application
    Filed: June 19, 2020
    Publication date: February 23, 2023
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Martyn SYMMONS, Keith RAY
  • POLYPEPTIDES WHICH BIND TO INTERLEUKIN-6 RECEPTOR (IL-6R)
    Publication number: 20220380475
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: March 18, 2022
    Publication date: December 1, 2022
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • POLYPEPTIDES
    Publication number: 20220363769
    Abstract: There are provided inter alia polypeptides capable of inhibiting IL-7 and/or L-TSLP binding to IL-7R (IL-7R), as well as to constructs and pharmaceutical compositions comprising these polypeptides.
    Type: Application
    Filed: May 24, 2022
    Publication date: November 17, 2022
    Inventors: Scott CROWE, Mike WEST, Kevin ROBERTS, Tim CARLTON, Luana MAGGIORE, Marion CUBITT, Lurdes DUARTE, Martyn SYMMONS, Keith RAY
  • POLYPEPTIDES
    Publication number: 20220332810
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Application
    Filed: May 20, 2022
    Publication date: October 20, 2022
    Inventors: Scott CROWE, Marion CUBITT, Tim CARLTON, Luana MAGGIORE, Lurdes DUARTE, Kevin ROBERTS, Mike WEST
  • POLYPEPTIDES
    Publication number: 20220242945
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
    Type: Application
    Filed: June 19, 2020
    Publication date: August 4, 2022
    Inventors: Scott CROWE, Marion CUBITT, Tim CARLTON, Luana MAGGIORE, Lurdes DUARTE, Kevin ROBERTS, Mike WEST
  • Polypeptides which bind to interleukin-6 receptor (IL-6R)
    Patent number: 11401327
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 2, 2022
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • POLYPEPTIDES
    Publication number: 20210317195
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.
    Type: Application
    Filed: November 17, 2020
    Publication date: October 14, 2021
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton
  • Compositions
    Patent number: 10980748
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: April 20, 2021
    Assignee: VHsquared Ltd.
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • COMPOSITIONS
    Publication number: 20200368167
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 26, 2020
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • POLYPEPTIDES
    Publication number: 20200317769
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: March 17, 2020
    Publication date: October 8, 2020
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray
  • POLYPEPTIDES
    Publication number: 20200291108
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: January 23, 2020
    Publication date: September 17, 2020
    Inventors: SCOTT CROWE, TIM CARLTON, MARION CUBITT, KEVIN ROBERTS, LUANA MAGGIORE, MIKE WEST, KEITH RAY
  • Compositions
    Patent number: 10772839
    Abstract: There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: September 15, 2020
    Assignee: VHsquared Limited
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Gary Whale, John Wahlich, Mike Frodsham
  • Polypeptides
    Patent number: 10633438
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: April 28, 2020
    Assignee: VHsquared Limited
    Inventors: Scott Crowe, Mike West, Kevin Roberts, Tim Carlton, Luana Maggiore, Marion Cubitt, Keith Ray
  • COMPOSITIONS
    Publication number: 20190307891
    Abstract: There is provided inter alia a composition comprising a TNF-alpha binding polypeptide and an IL-6R binding polypeptide.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 10, 2019
    Inventors: SCOTT CROWE, KEVIN ROBERTS, TIM CARLTON, LUANA MAGGOIRE, MARION CUBITT, MIKE WEST, KEITH RAY
  • Polypeptides
    Publication number: 20190092855
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Application
    Filed: July 20, 2018
    Publication date: March 28, 2019
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray